A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB (CP-690,550) IN CHINESE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE CONVENTIONAL SYNTHETIC DMARD
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB (CP-690,550) IN CHINESE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE CONVENTIONAL SYNTHETIC DMARD
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.
Inclusion Criteria:
Exclusion Criteria:
Hefei, Anhui 230022, China
Chongqing, Chongqing Municipality 400038, China
Shijiazhuang, Hebei 050051, China
Harbin, Heilongjiang 150001, China
Wuhan, Hubei 430022, China
Changzhou, Jiangsu 213003, China
Suzhou, Jiangsu 215006, China
Chengdu, Sichuan 610041, China
Tianjin, Tianjin Municipality 300052, China
Beijing, 100053, China